Xiu et al., 2022 - Google Patents
Gp350-anchored extracellular vesicles: promising vehicles for delivering therapeutic drugs of B cell malignanciesXiu et al., 2022
View HTML- Document ID
- 10046099926121277602
- Author
- Xiu H
- Nan X
- Guo D
- Wang J
- Li J
- Peng Y
- Xiong G
- Wang S
- Wang C
- Zhang G
- Yang Y
- Cai Z
- Publication year
- Publication venue
- Asian journal of pharmaceutical sciences
External Links
Snippet
Although chimeric antigen receptor-modified (CAR) T cell therapy has been successfully applied in the treatment of acute B lymphocytic leukemia, its effect on Burkitt lymphoma (BL) and chronic B lymphocytic leukemia (B-CLL) is unsatisfactory. Moreover, fatal side effects …
- 239000003814 drug 0 title abstract description 32
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Re et al. | HIV and lymphoma: from epidemiology to clinical management | |
| Shrivastava et al. | Exosome-mediated stable epigenetic repression of HIV-1 | |
| US20220280639A1 (en) | Compositions and methods for delivery of rna interference agents to immune cells | |
| JP2021523110A (en) | Nanoparticles for gene expression and their use | |
| WO2016189532A1 (en) | Targeted lipid particles for systemic delivery of nucleic acid molecules to leukocytes | |
| Xiu et al. | Gp350-anchored extracellular vesicles: promising vehicles for delivering therapeutic drugs of B cell malignancies | |
| JP2003513911A (en) | Therapy for human cancer using cisplatin and other drugs or genes encapsulated in liposomes | |
| Ci et al. | Delivery strategies in treatments of leukemia | |
| JP7479399B2 (en) | Tailored immunosuppressant nanovesicle delivery system for cancer tumors | |
| JP2018537472A (en) | Use of proliferating hematopoietic stem / progenitor cell population | |
| CN112135639A (en) | Cell assembly-mediated delivery of checkpoint inhibitors for cancer immunotherapy | |
| Ye et al. | Recent advances of nanodrug delivery system in the treatment of hematologic malignancies | |
| CN114404571A (en) | Chemotherapy drug loaded and TIGIT over-expressed engineered drug loaded cell membrane vesicle, and preparation method and application thereof | |
| US20120195869A1 (en) | Sickled Erythrocytes with Anti-tumor Agents Induce Tumor Vaso-occlusion and Tumoricidal Effects | |
| Pham et al. | Endosomal escape of nucleic acids from extracellular vesicles mediates functional therapeutic delivery | |
| US20210128725A1 (en) | Cytotoxic lipid particles targeted to tumor-associated myeloid cells (tamcs) and synergized with radiation therapy for treating glioblastoma | |
| Singh et al. | CD44 receptor targeted nanoparticles augment immunity against tuberculosis in mice | |
| Pei et al. | Multitargeted immunomodulatory therapy for viral myocarditis by engineered extracellular vesicles | |
| US20240279591A1 (en) | Compositions comprising spherical particles and uses of same | |
| CA3140668A1 (en) | Ca2 compositions and methods for tunable regulation | |
| CN113546056B (en) | Preparation method and application of biomimetic nano-protective agent for detoxification of cardiac and systemic toxicity of doxorubicin | |
| DE69230491T2 (en) | TRANSFORMED CELLS FOR THE PREVENTION OR TREATMENT OF VIRUS-INDUCED DISEASES, PARTICULARLY PATHOGENIC RETROVIRUS | |
| WO2013022827A1 (en) | Method of treating acute myelogenous leukemia | |
| EP3653201A1 (en) | Novel nanoparticles of antiretroviral drugs, their preparation and their use for the treatment of viral infections | |
| JP7636330B2 (en) | Drug delivery system containing oxidized cholesterol - Patents.com |